Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...

A new study led by Baylor College of Medicine and presented at the American College of Cardiology’s Annual Scientific Session together with World Congress of Cardiology found that an oral PCSK9 ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

Merck & Co. is betting big on its oral PCSK9 inhibitor. Buoyed by midphase results, the Big Pharma has kicked off a clutch of late-stage studies including a cardiovascular outcomes trial that will ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the arteries and cardiovascular health. Now, a study led by the University of ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...

Please provide your email address to receive an email when new articles are posted on . “The PCSK9 inhibitors have all been given by injection, every 2 to 4 weeks for the fully human monoclonal ...

The upregulation of PCSK9 expression in endothelial cells of diabetic patients induces ubiquitination of VEGFR2 and inhibits the VEGFR2/ AKT/eNOS -ERK signaling pathway by promoting the interaction of ...

An investigational drug, currently known as AZD0780, lowers low-density-lipoprotein cholesterol (LDL-C) to target levels in most patients whose cholesterol is still over target despite statin therapy, ...

A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study. The study was presented by Christie Ballantyne, MD, ...